| Literature DB >> 31637305 |
Jiangning Yin1, Jun Jiang2, Huajun Wang3, Guoyuan Lu4.
Abstract
BACKGROUND: We aim to investigate the protective effects and potential mechanisms in specneuzhenide (SPE) on renal injury in rats with diabetic nephropathy (DN).Entities:
Keywords: Diabetic nephropathy; Inflammation; Podocyte; Renal injury; Slit diaphragm protein; Specnuezhenide
Year: 2019 PMID: 31637305 PMCID: PMC6778394 DOI: 10.1515/med-2019-0085
Source DB: PubMed Journal: Open Med (Wars)
Regulatory effects of SPE on glucose
| Group | Baseline | Week 4 | Week 8 | Week 12 | Week 16 |
|---|---|---|---|---|---|
| Control | 4.46 ± 0.02 | 4.49 ± 0.02 | 4.61 ± 0.08 | 4.51 ± 0.06 | 4.47 ± 0.03 |
| Model group | 4.48 ± 0.04 | 23.78 ± 0.21 | 25.53 ± 0.68 | 26.21 ± 0.62 | 25.30 ± 0.52* |
| SPE-L | 4.41 ± 0.02 | 23.34 ± 0.97 | 21.32 ± 0.96 | 16.96 ± 0.82 | 15.77 ± 0.79† |
| SPE-H | 4.45 ± 0.03 | 17.44 ± 0.68 | 12.78 ± 0.82 | 9.39 ± 0.64 | 8.46 ± 0.72† |
P < 0.05 versus control; †P < 0.01 versus model group.
Comparison of 24 h urine protein in each group
| Group | Baseline | Week 4 | Week 8 | Week 12 | Week 16 |
|---|---|---|---|---|---|
| Control | 7.02 ± 0.63 | 7.68 ± 0.03 | 6.81 ± 0.16 | 6.42 ± 0.06 | 7.37 ± 0.23 |
| Model group | 7.37 ± 0.42 | 26.88 ± 0.49 | 28.44 ± 0.10 | 28.40 ± 0.25 | 32.64 ± 0.41* |
| SPE -L | 7.28 ± 0.61 | 24.55 ± 0.83 | 26.88 ± 0.94 | 25.98 ± 0.81 | 25.01 ± 0.86 † |
| SPE -H | 7.14 ± 0.64 | 21.39 ± 0.72 | 23.47 ± 0.73 | 24.49 ±0.75 | 21.76 ± 0.95 † |
P < 0.01 versus control; †P < 0.05 versus model group.
Effects of SPE on body weight, renal weight and index in DN rats
| Group | Weight (g) | Renal weight (g) | Renal index (×100) |
|---|---|---|---|
| Control | 406.32 ± 11.54 | 1.57 ± 0.04 | 0.38 ± 0.0045 |
| Model group | 327.83 ± 4.83 * | 1.74 ± 0.05 * | 0.53 ± 0.0201 * |
| SPE-L | 336.73 ± 3.09 | 1.66 ± 0.09 | 0.49 ± 0.0112 |
| SPE-H | 355.60 ± 5.19 † | 1.60 ± 0.12 † | 0.45 ± 0.0105 † |
P < 0.05 versus control; †P < 0.01 versus model group.
Regulatory effects of SPE on serum IL-1β, IL-6 and TNF-α
| Group | Serum IL-1β (pg/mL) | Serum IL-6 (pg/mL) | Serum TNF-α (pg/mL) |
|---|---|---|---|
| Control | 10.10 ± 2.18 | 20.64 ± 2.03 | 16.96 ± 5.23 |
| Model group | 35.06 ± 3.18 * | 40.10 ± 2.72 * | 41.27 ± 3.02 * |
| SPE-L | 27.45 ± 1.66 † | 36.05 ± 1.49 | 32.33 ± 5.84 † |
| SPE-H | 26.34 ± 1.32 # | 32.80 ± 1.52 † | 27.98 ± 4.25 # |
P < 0.05 versus control; †P < 0.05 versus model group; #P < 0.01 versus model group.
Regulatory effects of SPE on renal IL-1β, IL-6, SOD, MDA, podocin and CD2AP
| Group | Renal IL-1β (pg/mL) | Renal IL-6 (pg/mL) | Renal TNF-α (pg/mL) | Renal SOD (U/mL) | Renal MDA (nmol/mL) | Renal podocin | Renal CD2AP |
|---|---|---|---|---|---|---|---|
| Control | 3.67 ± 0.37 | 6.80 ± 0.62 | 4.71 ± 0.89 | 22.57 ± 0.08 | 36.56 ± 9.26 | 0.70 ±0.03 | 0.73 ± 0.02 |
| Model group | 9.59 ± 1.37 * | 9.71 ± 0.39 * | 11.06 ± 0.32 * | 9.09 ± 0.81 * | 91.56 ± 8.56 * | 0.06 ± 0.02 * | 0.07 ± 0.03 * |
| SPE-L | 7.37 ± 0.79 † | 9.65 ± 0.74 | 10.74 ± 0.86 | 16.43 ± 0.92 † | 67.48 ± 5.71 † | 0.21 ±0.03 † | 0.19 ± 0.04 † |
| SPE-H | 5.55 ± 0.67 △ | 7.23 ± 0.56 † | 8.17 ± 0.75 # | 22.31 ± 0.99 † | 53.68 ± 7.44 † | 0.51 ±0.05 3 | 0.49 ± 0.05 # |
P < 0.05 versus control; †P < 0.05 versus model group; #P < 0.01 versus model group.
Figure 1HE staining indicating the pathological changes in renal tissues. CON, control; MOD: model group; SPE-L, low dose group of SPE; SPE-H, high dose group of SPE.
Figure 2PAS staining for the pathological changes in renal tissues. CON, control; MOD: model group; SPE-L, low dose group of SPE; SPE-H, high dose group of SPE.